138232-44-7

Usage

Uses

Used in Organic Synthesis:
1-((Benzyloxy)carbonyl)pyrrolidin-3-yl methanesulfonate is used as a protecting group for amine functionality in organic chemistry reactions. It helps prevent unwanted side reactions involving the amine group, allowing for selective reactions to occur at other sites on the molecule.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-((Benzyloxy)carbonyl)pyrrolidin-3-yl methanesulfonate is used as a building block for the synthesis of various pharmaceuticals and bioactive molecules. Its incorporation into drug candidates can enhance their pharmacological properties, improving their efficacy and selectivity.
Used in Chemical Reactions:
The methanesulfonate group in 1-((Benzyloxy)carbonyl)pyrrolidin-3-yl methanesulfonate acts as a leaving group in chemical reactions. This property facilitates the formation of specific chemical bonds, enabling the synthesis of complex molecules with desired structural features.
Used in Pharmaceutical Industry:
1-((Benzyloxy)carbonyl)pyrrolidin-3-yl methanesulfonate is used as a key intermediate in the synthesis of various pharmaceuticals. Its versatility and reactivity make it a valuable component in the development of new drugs with improved therapeutic profiles.
Used in Bioactive Molecule Synthesis:
In the synthesis of bioactive molecules, 1-((Benzyloxy)carbonyl)pyrrolidin-3-yl methanesulfonate is used to introduce specific functional groups and structural elements. This allows for the creation of molecules with targeted biological activities, such as enzyme inhibition or receptor modulation.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 95656-88-5 benzyl 3-hydroxypyrrolidine-1-carboxylate 
• 130312-02-6 benzyl 3-oxopyrrolidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 188846-99-3 (+/-)-3-cyanopyrrolidine-1-carboxylic acid benzyl ester 
• 1196044-28-6 C₁₇H₂₁NO₆ 
• 1035173-74-0 benzyl 3-(chlorosulfonyl)pyrrolidine-1-carboxylate 
• 930299-97-1 benzyl 3-(acetylthio)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF

A compound of Formula (I) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 and Y are as defined herein.

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity

Wogonin, a natural product isolated from the plant Scutellaria baicalensis, has been shown to be a potent and selective inhibitor of CDK9. With the purpose of investigating the activity and selectivity of this chemical scaffold, several series of wogonin derivatives were prepared and screened for CDK9 inhibition and cellular antiproliferative activity. Among these compounds, the drug-like compound 51 showed potent activity against CDK9 (IC50 = 19.9 nM) and MV4-11 cell growth (IC50 = 20 nM). In addition, compound 51 showed much improved physicochemical properties, such as water solubility, compared with the parent compound wogonin. The follow-up studies showed that the compound 51 is selective toward CDK9-overexpressing cancer cells over normal cells. Preliminary mechanism studies on the anticancer effect indicated that 51 inhibited the proliferation of MV4-11 cells via caspase-dependent apoptosis. In addition, highlighted compound 51 showed significant antitumor activity in mouse acute myeloid leukemia (AML) models without producing apparent toxic effects in vivo, which gave us a new tool for further investigation of CDK9-targeted inhibitor as a potential antitumor drug especially for AML.

PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS

The present invention relates to compounds of formula (I) useful as inhibitors of one or more histone demethylses, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and the compounds for use in methods for the treatment of various disorders. Formula (I): or a salt thereof, wherein: A is selected from the group consisting of:

A library of conformationally restricted saturated heterocyclic sulfonyl chlorides

An approach to the synthesis of conformationally restricted saturated heterocyclic sulfonyl chlorides is described. Being guided by the principle of diversity-oriented conformational restriction, a mini-library of saturated heterocyclic sulfonyl chlorides

C-H bond functionalization via hydride transfer: Direct coupling of unactivated alkynes and sp3 C-H bonds catalyzed by platinum tetraiodide

We report a catalytic intramolecular coupling between terminal unactivated alkynes and sp3 C-H bonds via through-space hydride transfer (HT-cyclization of alkynes). This method enables one-step preparation of complex heterocyclic compounds by α

Nitrilase-catalyzed enantioselective synthesis of pyrrolidine- And piperidinecarboxylic acids

The enantioselective synthesis of the nonproteinogenic amino acids β-proline and nipecotic acids from their readily available nitriles is achieved in high enantiomeric excess by commercially available nitrilases. The presented procedure comprises not more than 4 steps, thus considerably reducing the multiple steps generally required. Amide formation is also observed for specific heterocyclic nitriles.

(S)-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

The novel (S)-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-n phthyridine-3-carboxylic acid, lower alkyl esters and pharmaceutically acceptable salts thereof are described as well as a method for its manufacture, formulation, and use in treating bacterial infections.

Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent

Novel quinolone and naphthyridine antibacterial agents are herein described having improved in vivo activity both orally and subcutaneously where the 7-side chain of such compounds contain an α-amino acid; also described are its corresponding optical isomers, methods of preparation as well as compositions and methods of treating infections diseases.